Chemomab Therapeutics (CMMB) Non Operating Income (2018 - 2019)
Chemomab Therapeutics' (CMMB) quarterly Non Operating Income came in at $12.5 million in Q3 2019, up 20656.67% on a YoY basis from N/an in Q3 2018, and up 549.28% quarter-over-quarter from -$2.8 million in Q2 2019.
Powered by 
Analysis
Chemomab Therapeutics (CMMB) Non Operating Income (2018 - 2019) Analysis & Trends
Chemomab Therapeutics (CMMB) has reported Non Operating Income for 2 consecutive years, with $12.5 million the latest figure, recorded in Q3 2019.
- For the quarter ending Q3 2019, Non Operating Income rose 20656.67% year-over-year to $12.5 million; the trailing twelve-month figure through Sep 2019 stood at $21.2 million (changed N/A YoY), and the FY2025 full-year result was $572000.0, down 27.96% from the prior year.
- Non Operating Income grew to $12.5 million in Q3 2019 per CMMB's latest filing, from -$2.8 million in the prior quarter.
- Across five years, Non Operating Income topped out at $12.9 million in Q1 2019 and bottomed at -$2.8 million in Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -73.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 387.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 234.30 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Chemomab Therapeutics | 17.03 Mn | 17.03 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2019 | 12.45 Mn |
| Jun 30, 2019 | -2.77 Mn |
| Mar 31, 2019 | 12.87 Mn |
| Dec 31, 2018 | -1.33 Mn |
| Sep 30, 2018 | 60,000.00 |
| Jun 30, 2018 | 806,000.00 |
| Mar 31, 2018 | 76,000.00 |